Bilazap M Tablet for Allergies, Sneezing & Runny Nose

Bilazap M 20mg/10mg Tablet:

Product Introduction

Bilazap M 20mg/10mg Tablet is an innovative combination medication that brings together two powerful therapeutic agents to provide comprehensive relief from allergic conditions. This dual-action formulation combines Bilastine (20mg), a second-generation antihistamine, with Montelukast (10mg), a selective leukotriene receptor antagonist. Together, these components target multiple pathways involved in allergic responses, offering enhanced efficacy compared to either medication used alone.

Bilastine works by selectively blocking histamine H1 receptors, effectively reducing allergy symptoms such as sneezing, itching, runny nose, and watery eyes without causing significant sedation. This modern antihistamine is designed to provide 24-hour relief with minimal passage through the blood-brain barrier, resulting in reduced drowsiness compared to older antihistamines. Complementing this action, Montelukast inhibits leukotriene receptors, which are key mediators in allergic inflammation and bronchoconstriction. By targeting this pathway, Montelukast helps reduce airway inflammation, nasal congestion, and bronchial hyperreactivity.

The synergistic effect of these two active ingredients makes Bilazap M particularly valuable for patients suffering from allergic conditions with both upper and lower respiratory symptoms. This combination is especially beneficial for those with allergic rhinitis accompanied by asthmatic components or for patients who have not achieved adequate symptom control with single-agent therapy.

Healthcare providers often prescribe Bilazap M for managing moderate to severe allergic rhinitis (seasonal or perennial), particularly when accompanied by asthmatic symptoms or when patients need comprehensive control of both histamine and leukotriene-mediated allergic manifestations. The once-daily dosing schedule enhances patient compliance, while the complementary mechanisms of action provide consistent symptom relief throughout the day and night.

Bilazap M represents an advancement in allergy management by addressing multiple pathophysiological mechanisms involved in allergic responses, offering patients a convenient and effective solution for controlling complex allergic conditions with a single tablet.

🌼 Bilazap M 20mg/10mg Tablet – Get fast, long-lasting allergy relief with this trusted combination medicine.

Bilazap M 20mg/10mg Tablet

💊 Type: Prescription Medicine

🏢 Manufacturer: Glenmark Pharmaceuticals Ltd

🧪 Composition: Bilastine (20mg) + Montelukast (10mg)

🌡️ Storage: Store below 30°C in a cool, dry place

🔁 Similar Medicines: [Click here to view substitutes]

Key Composition & Ingredients

Bilastine (20mg): A non-sedating, second-generation H1-receptor antagonist
Montelukast (10mg): A selective leukotriene receptor antagonist (LTRA)
Inactive ingredients may include: microcrystalline cellulose, sodium starch glycolate, magnesium stearate, silicon dioxide, and pharmaceutical-grade coating materials (specific excipients may vary by manufacturer)

Uses of Bilazap M Tablet

Treatment of moderate to severe allergic rhinitis (seasonal and perennial)
Management of allergic conditions with both upper and lower respiratory symptoms
Relief of allergic rhinitis in patients with co-existing asthma
Treatment of allergic rhinoconjunctivitis (combined nasal and eye symptoms)
Management of urticaria (hives) with respiratory involvement
Prevention of exercise-induced bronchoconstriction
Relief from outdoor and indoor allergen exposure
Seasonal allergy management during high pollen periods
Treatment of persistent allergic symptoms unresponsive to single-agent therapy
Comprehensive control of daytime and nighttime allergy symptoms

Benefits of Bilazap M Tablet

Dual-Action Relief: Targets both histamine and leukotriene pathways for comprehensive symptom control
Rapid Onset: Bilastine component begins acting within 1 hour of administration
24-Hour Protection: Once-daily dosing provides round-the-clock symptom relief
Minimal Sedation: Bilastine has low central nervous system penetration, reducing drowsiness
Reduced Nasal Congestion: Montelukast effectively addresses nasal congestion, often resistant to antihistamines alone
Decreased Airway Inflammation: Helps reduce bronchial hyperreactivity and inflammatory response
Improved Sleep Quality: Nighttime symptom control leads to better rest
Enhanced Quality of Life: Comprehensive symptom management improves daily functioning
Convenient Dosing: Single tablet simplifies treatment regimen
Complementary Action: Addresses multiple allergic pathways for superior efficacy compared to monotherapy

How Bilazap M Tablet Works (Mechanism of Action)

Bilazap M works through two complementary mechanisms that target different aspects of the allergic response:

Bilastine (20mg) - Functions as a highly selective histamine H1-receptor antagonist:
- Competitively and selectively binds to peripheral H1 receptors
- Blocks the action of histamine, a key mediator released during allergic reactions
- Prevents histamine-induced symptoms such as sneezing, itching, rhinorrhea, and urticaria
- Has minimal penetration across the blood-brain barrier, resulting in reduced sedation
- Demonstrates no significant affinity for other receptors, minimizing side effects
- Provides rapid onset (within 1 hour) and long duration (24 hours) of action
Montelukast (10mg) - Acts as a selective leukotriene receptor antagonist:
- Binds with high affinity to cysteinyl leukotriene receptors (CysLT1)
- Blocks the action of leukotrienes, potent inflammatory mediators produced during allergic responses
- Inhibits bronchoconstriction, mucus secretion, and vascular permeability
- Reduces eosinophil migration to sites of inflammation
- Particularly effective for nasal congestion and bronchial symptoms
- Provides anti-inflammatory action in both upper and lower airways

The combined effect of blocking both histamine and leukotriene pathways provides more comprehensive control of allergic symptoms than either agent alone. This dual approach addresses the immediate allergic response (primarily mediated by histamine) as well as the delayed inflammatory phase (significantly driven by leukotrienes).

Dosage of Bilazap M Tablet

Daily Dose

Adults and adolescents (12 years and older): One tablet (Bilastine 20mg + Montelukast 10mg) once daily
Preferably taken in the evening: For optimal control of night and early morning symptoms
Consistency: Should be taken at approximately the same time each day
Duration: As prescribed by healthcare provider, typically continued throughout the allergy season or exposure period

Missed Dose

Take as soon as remembered if within 12 hours of the usual time
If more than 12 hours have passed, skip the missed dose and continue with the next regularly scheduled dose
Do not double the dose to make up for a missed tablet
Return to regular dosing schedule afterward

Overdose

Symptoms may include headache, drowsiness, thirst, and abdominal pain
In case of significant overdose, seek immediate medical attention
Treatment is primarily supportive and symptomatic
No specific antidote is available
Consider contacting poison control center for guidance

Mode of Action of Bilazap M Tablet

Bilazap M provides comprehensive allergy relief through a dual mechanism targeting distinct allergic pathways:

Bilastine Component (20mg):

Selectively antagonizes peripheral H1 histamine receptors
Prevents histamine from binding to its receptors, thereby inhibiting the immediate allergic response
Has minimal activity at muscarinic, α1-adrenergic, or D2-dopaminergic receptors, reducing anticholinergic side effects
Demonstrates minimal central nervous system penetration due to limited blood-brain barrier crossing
Achieves peak plasma concentrations in 1-1.5 hours
Has a terminal elimination half-life of 12-14 hours, allowing once-daily dosing
Is primarily excreted unchanged in feces and urine

Montelukast Component (10mg):

Specifically binds to cysteinyl leukotriene type-1 (CysLT1) receptors
Blocks the physiological actions of leukotrienes LTC4, LTD4, and LTE4
Inhibits the sustained phase of allergic inflammation
Reduces airway edema, smooth muscle contraction, and cellular activity associated with the inflammatory process
Particularly effective in reducing nasal congestion and bronchial hyperresponsiveness
Has a bioavailability of approximately 64% and is extensively metabolized in the liver
Achieves peak plasma levels in 3-4 hours
Demonstrates a half-life of 2.7-5.5 hours but provides 24-hour clinical efficacy

The combination provides complementary coverage of both early and late phases of allergic reactions, targeting multiple mediators and symptoms for comprehensive relief.

How to Use Bilazap M Tablet

Directions for Use

Take one tablet daily, preferably in the evening.
Swallow the tablet whole with a glass of water.
Can be taken with or without food, but consistent timing relative to meals is recommended.
For allergic rhinitis, best results may be achieved when taken regularly throughout the allergy season.
Do not crush, chew, or break the tablet as this may affect the drug release profile.
The tablet should be taken at least 1 hour before or 2 hours after a meal for optimal bilastine absorption.
Avoid taking with grapefruit juice or other fruit juices, as these may decrease drug effectiveness.
For seasonal allergies, consider starting treatment before expected allergen exposure when possible.
Continue taking as prescribed even after symptoms improve to maintain control.
Store at room temperature away from moisture and heat.

Side Effects of Bilazap M Tablet

Common Side Effects & How to Manage Them

Headache: Usually mild and transient. Stay well-hydrated and rest if needed; over-the-counter pain relievers may help if approved by your doctor.
Fatigue: Ensure adequate rest; take the medication in the evening if drowsiness occurs.
Dry Mouth: Sip water frequently, chew sugar-free gum, or use alcohol-free mouthwash.
Mild Gastrointestinal Disturbances: Taking with food may help reduce stomach discomfort.
Dizziness: Rise slowly from sitting or lying positions; avoid driving or operating machinery if affected.

Less Common Side Effects

Nausea or Abdominal Pain: Usually mild and transient; consult doctor if persistent.
Increased Dream Activity: Generally not concerning but report if disturbing.
Mild Behavioral Changes: Particularly in children; report any unusual behavior to healthcare provider.
Muscle or Joint Pain: Report persistent symptoms to healthcare provider.
Upper Respiratory Tract Infection: Maintain good hygiene practices and report worsening symptoms.

Rare but Serious Side Effects (Seek Medical Attention)

Severe allergic reactions (rash, itching, swelling, severe dizziness, difficulty breathing)
Mood or behavior changes (agitation, anxiety, depression, hallucinations)
Liver problems (yellowing of skin/eyes, dark urine, persistent nausea, stomach pain)
Neuropsychiatric events (suicidal thoughts, unusual behaviors)
Eosinophilic conditions (flu-like symptoms, rash, worsening breathing problems)

Safety Advice for Bilazap M Tablet

Alcohol

Moderate Caution: Alcohol may enhance drowsiness or dizziness, although bilastine has minimal sedative effects compared to older antihistamines.
Limit alcohol consumption while taking Bilazap M.

Pregnancy

Category C: Risk cannot be ruled out.
Not routinely recommended during pregnancy unless clearly needed.
Consult healthcare provider to weigh potential benefits against risks.
Animal studies have shown variable effects; human data are limited.

Breastfeeding

Limited data available on excretion into breast milk.
Use with caution during breastfeeding.
Consider the importance of the medication to the mother.
Monitor the infant for possible side effects if used during lactation.

Driving

Caution advised: While bilastine is less likely to cause drowsiness than first-generation antihistamines, individual responses vary.
Assess your response to the medication before driving or operating machinery.
Avoid these activities if you experience drowsiness or dizziness.

Kidney

Use with caution in severe renal impairment.
Dose adjustment may be necessary for patients with creatinine clearance <30 mL/min.
Regularly monitor renal function in patients with kidney disease.

Liver

Montelukast is extensively metabolized in the liver.
Use with caution in patients with hepatic impairment.
Dose adjustment generally not required for mild to moderate hepatic impairment.
Monitor liver function periodically during long-term therapy.

Children

Not recommended for children under 12 years of age.
Safety and efficacy have not been established in younger children for this combination.
Alternative age-appropriate formulations of the individual components may be available for younger patients.

Older Patients

No specific dose adjustment required for elderly patients with normal renal function.
May be more sensitive to side effects; monitor closely.
Consider potential drug interactions with other medications commonly used by elderly patients.

Lactation

Limited data available on excretion into breast milk.
Decision to continue/discontinue breastfeeding or the medication should consider the importance of the drug to the mother.
Monitor breastfed infants for drowsiness, irritability, or poor feeding.

Allergy

Contraindicated in patients with known hypersensitivity to bilastine, montelukast, or any component of the formulation.
Previous allergic reactions to either active ingredient preclude the use of this combination.
Cross-reactivity between different leukotriene modifiers is possible.

Warnings & Precautions of Bilazap M Tablet

Neuropsychiatric Events: Monitor for behavior and mood changes, including suicidal thoughts, especially when starting therapy or changing doses.
Eosinophilic Conditions: Be alert for symptoms such as worsening pulmonary symptoms, cardiac complications, or neuropathy in patients taking montelukast.
Churg-Strauss Syndrome: Rare cases have been reported, typically when reducing oral corticosteroid therapy; watch for worsening pulmonary symptoms, cardiac complications, or neuropathy.
P-glycoprotein Inhibitors: Concomitant use with P-gp inhibitors (e.g., ketoconazole, erythromycin, cyclosporine) may increase bilastine levels.
QT Prolongation: Use with caution in patients with risk factors for QT prolongation or who are taking other medications known to prolong the QT interval.
Phenylketonuria: Some formulations may contain phenylalanine; check with pharmacist if you have phenylketonuria.
Acute Asthma Attacks: Not appropriate for treatment of acute asthma attacks; proper rescue medication should be available.
Aspirin Sensitivity: Patients with known aspirin sensitivity may also have cross-sensitivity to montelukast.
Reduction of Corticosteroids: Do not abruptly substitute this medication for inhaled or oral corticosteroids; gradual reduction under medical supervision is necessary.
Exercise-Induced Bronchoconstriction: For prevention, take at least 2 hours before exercise; additional doses should not be taken within 24 hours.

Interactions with Bilazap M Tablet

Drug-Drug Interactions

P-glycoprotein Inhibitors (ketoconazole, erythromycin, cyclosporine, ritonavir): May increase bilastine concentration; avoid concomitant use.
CYP3A4 Inhibitors (ketoconazole, erythromycin, clarithromycin, itraconazole): May increase montelukast concentrations; generally no dose adjustment needed but monitor for side effects.
CYP3A4 Inducers (phenytoin, phenobarbital, rifampin): May decrease montelukast effectiveness; monitor clinical response.
Phenobarbital and Rifampicin: May reduce bilastine efficacy through increased clearance.
QT-Prolonging Medications (certain antiarrhythmics, macrolides, fluoroquinolones): Potential additive effect on QT interval; caution advised.
Sedatives and CNS Depressants: Potential additive effects on CNS; monitor for increased sedation.
Opioid Analgesics: May increase risk of constipation with bilastine.
Oral Anticoagulants and Non-steroidal Anti-inflammatory Drugs (NSAIDs): Increased risk of bleeding when used with montelukast; monitor INR if on warfarin.

Drug-Food Interactions

Food: Delays and decreases bilastine absorption; take at least 1 hour before or 2 hours after meals.
Grapefruit Juice: May affect metabolism of both active ingredients; avoid concurrent use.
Fruit Juices: May decrease absorption of bilastine; take with water only.
High-Fat Meals: May reduce the rate and extent of bilastine absorption.
Apple, orange, and grapefruit juice: May reduce bilastine bioavailability by approximately 30%.

Contraindications of Bilazap M Tablet

Bilazap M is contraindicated in the following conditions:

Hypersensitivity to bilastine, montelukast, or any component of the formulation
Severe renal impairment (creatinine clearance <30 mL/min) without appropriate dose adjustment
History of angioedema with previous leukotriene receptor antagonist use
Acute asthma attacks or status asthmaticus (not for rescue therapy)
Severe hepatic impairment (Child-Pugh class C)
Concomitant use with strong P-glycoprotein inhibitors
Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (if formulation contains lactose)
Children under 12 years of age (safety and efficacy not established)
Pregnancy, unless clearly necessary after risk-benefit assessment
Known QT prolongation or concurrent use of drugs known to prolong QT interval without careful monitoring

Safety Measures & FDA Pregnancy Category

Bilazap M components are generally classified under FDA Pregnancy Category C, indicating that risk cannot be ruled out. Animal reproduction studies have shown adverse effects on the fetus, and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use despite potential risks.

Safety measures include:

Regular monitoring for neuropsychiatric symptoms
Periodic liver function tests during long-term therapy
Caution when discontinuing concomitant corticosteroids
ECG monitoring in patients with risk factors for QT prolongation
Avoidance in known hypersensitivity to either component
Medical supervision for patients with phenylketonuria (if formulation contains aspartame)
Careful risk-benefit assessment before use in pregnancy

Diet & Lifestyle Advice

Allergen Avoidance: Identify and minimize exposure to known allergens (dust mites, pollen, pet dander, etc.)
Hydration: Maintain adequate fluid intake to help thin mucus secretions
Air Quality: Consider using air purifiers with HEPA filters in bedrooms and living areas
Bedding: Use allergen-proof mattress and pillow covers
Humidity Control: Maintain indoor humidity between 30-50% to minimize mold and dust mite growth
Home Cleaning: Regular dusting with damp cloths and vacuuming with HEPA filters
Pet Management: Keep pets out of bedrooms if allergic to animal dander
Smoking: Avoid smoking and secondhand smoke exposure
Outdoor Activities: Monitor pollen counts and limit outdoor activities during peak pollen times
Nutritional Guidance: Consider an anti-inflammatory diet rich in omega-3 fatty acids, fruits, and vegetables
Stress Management: Practice stress-reduction techniques, as stress may exacerbate allergic symptoms
Exercise: Moderate regular exercise can help improve overall immune function
Nasal Irrigation: Consider saline nasal irrigation to remove allergens and thin mucus
Shower Before Bed: Washing hair and showering before bedtime can remove pollen and reduce nighttime symptoms

Why Doctors Recommend This Medicine

Healthcare professionals recommend Bilazap M for several compelling reasons:

Comprehensive Symptom Control: The dual-action approach targets both histamine and leukotriene pathways, addressing a broader range of allergy symptoms than single-agent therapy.
Improved Management of Nasal Congestion: Montelukast effectively addresses nasal congestion, which is often inadequately controlled by antihistamines alone.
24-Hour Relief: Once-daily dosing provides round-the-clock symptom control.
Reduced Sedation: Bilastine offers effective antihistamine action with minimal sedative effects.
Better Compliance: Single tablet, once-daily regimen improves adherence compared to multiple medications or more frequent dosing.
Dual Pathway Targeting: Addresses both early and late phases of allergic reactions.
Management of Complex Allergies: Particularly effective for patients with allergic rhinitis and asthmatic components.
Improved Quality of Life: Comprehensive symptom control leads to better sleep, productivity, and overall well-being.
Reduced Need for Multiple Medications: May eliminate the need for additional rescue or symptomatic treatments.
Favorable Safety Profile: Both components have well-established safety records when used appropriately.

Substitutes of Bilazap M Tablet & Alternative Medicines

Similar Combination Products

Montair-AX (Montelukast + Levocetirizine)
Montek LC (Montelukast + Levocetirizine)
Romilast-H (Montelukast + Fexofenadine)
Histakind-M (Montelukast + Ebastine)
Allegra-M (Montelukast + Fexofenadine)

Individual Components

Bilastine alternatives: Bilaxten, Bilaryn, Albilastin
Montelukast alternatives: Singulair, Montair, Romilast, Montek, Ventair

Alternative Drug Classes

Other Antihistamines: Cetirizine, Levocetirizine, Fexofenadine, Loratadine, Desloratadine
Intranasal Corticosteroids: Fluticasone, Mometasone, Budesonide
Decongestants: Pseudoephedrine, Phenylephrine (for short-term use)
Mast Cell Stabilizers: Cromolyn sodium, Nedocromil
Anti-IgE Therapy: For severe allergic conditions (prescription only)

Non-Pharmacological Alternatives

Saline nasal irrigation
Allergen immunotherapy (allergy shots)
HEPA air purifiers
Allergen avoidance strategies
Nasal breathing exercises
Acupuncture (limited evidence)

Storage Guidelines

Store at room temperature between 15-30°C (59-86°F)
Keep away from direct sunlight and moisture
Store in the original package/container
Keep out of reach of children
Do not store in the bathroom
Protect from extreme temperature fluctuations
Do not use after the expiration date printed on the package
Do not remove from blister pack until ready to take
Discard any unused medication properly according to local regulations
Keep container tightly closed when not in use

User Feedback & Patient Concerns

Common feedback from patients using Bilazap M includes:

Positive Feedback:

Effective relief from multiple allergy symptoms, particularly nasal congestion
Minimal drowsiness compared to other allergy medications
Convenience of once-daily dosing
Improved sleep quality due to nighttime symptom control
Better daytime functioning and productivity

Common Concerns and Questions:

Time to onset of action (typically 1-3 hours for initial relief, with optimal effects after several days of regular use)
Duration of therapy (depends on nature of allergies; seasonal vs. perennial)
Interaction with other medications (always discuss with healthcare provider)
Whether medication can be stopped abruptly (generally safe but may result in return of symptoms)
Cost considerations compared to taking individual components separately

Management Suggestions:

For optimal results, take consistently at the same time each day
Allow 3-7 days of regular use to achieve maximum benefit
Report any unusual side effects to healthcare provider
Combine with allergen avoidance for best outcomes

Quick Tips for Bilazap M Tablet

Take on an empty stomach for optimal absorption of bilastine
Establish a consistent evening routine for taking the medication
Allow 24-72 hours for initial improvement; full benefits may take up to one week
Continue taking even when symptoms improve to maintain control
Avoid grapefruit juice and other fruit juices that may decrease effectiveness
Store at room temperature away from moisture and heat
Use in combination with allergen avoidance for best results
Keep track of symptom improvements to discuss with your doctor
Report unusual mood changes or behavioral symptoms promptly
For seasonal allergies, begin taking before allergen season starts when possible

Fact Box

Chemical Class

Bilastine: Second-generation piperidine antihistamine
Montelukast: Selective leukotriene receptor antagonist (quinoline derivative)

Habit Forming

Non-habit forming

Therapeutic Class

Antihistamine + Leukotriene receptor antagonist combination
Anti-allergic agent

Action Class

H1-receptor antagonist (Bilastine)
Cysteinyl leukotriene type-1 (CysLT1) receptor antagonist (Montelukast)

Useful Diagnostic Tests

Before or during treatment with Bilazap M, the following diagnostic tests may be helpful:

Skin prick testing to identify specific allergens
Serum IgE levels to assess allergic status
Complete blood count with differential (to evaluate eosinophilia)
Pulmonary function tests if asthmatic component is suspected
Liver function tests as baseline and periodically during long-term therapy
Renal function tests for patients with kidney disease
Radioallergosorbent test (RAST) for specific allergen identification
Nasal smear for eosinophils to confirm allergic rhinitis
Peak flow measurements for patients with asthmatic components

More Information & References

For additional information about Bilazap M and its components, consult:

World Allergy Organization (WAO) guidelines on allergic rhinitis management
American Academy of Allergy, Asthma & Immunology (AAAAI) treatment recommendations
European Academy of Allergy and Clinical Immunology (EAACI) position papers
British Society for Allergy and Clinical Immunology (BSACI) guidelines
Clinical pharmacology resources on antihistamines and leukotriene modifiers
Current medical literature on combination therapy for allergic conditions

Disclaimer

This information is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read here. If you think you may have a medical emergency, call your doctor or emergency services immediately. This medication should only be used under the supervision of a qualified healthcare provider. Individual responses to medications may vary. The information provided here is accurate to the best of our knowledge at the time of publication but may become outdated as new research becomes available.